logo®
Aix Scientifics®   Clinical Research Organisation

Le recenti notizie sui progetti dove Aix Scientifics® è responsabile

Si prega d'essere consapevole del fatto: con un clic su uno dei seguenti collegamenti, si lascia il sito web d'Aix Scientifics®. Aix Scientifics® non è responsabile per il disegno o il contenuto di uno di questi siti web. Per il contenuto inesatto, incompleto, illegale ed offensivo e le lesioni derivanti da queste la responsabilità è dalla parte del proprietario di questo sito web.

Alloksys Life Sciences BV 21.04.2008
After the 'APPIRED I' has been stopped due to external reasons (withdrawal of aprotinin). The Alloksys Life Sciences BV (Netherlands, www.alloksys.eu) could start the 'APPIRED II' trial. To establish the safety of intravenously administrated alkaline phosphatase in patients undergoing combined heart valve replacement and coronary artery bypass grafting (CABG) surgery with cardio-pulmonary bypass (CBP) (ClinicalTrials.gov-ID: NCT01144611). Subsequent studies are in preparation. E.G.F.
pfm medical ag 02.03.2010
Nach dem positiven Votum der Ethikkommssion konnte jetzt die Phase IV-Studie : Anterior Pelvic Prolapse Reconstruction with TiLOOP® Total 6 (ClinicalTrials.gov-ID: NCT01084889) der pfm medical AG, Köln, gestartet werden. E.G.F.
pfm medical ag 13.02.2009
The Data Savety Monitoring Board accepted to start the second part of the clinical investigation on safety and effectiveness of the Nit-Occlud® Lê VSD Spiral Coil System for VSD Occlusion (ClinicalTrials.gov-ID: NCT00390702). For the second part the pfm AG Cologne, Germany, will include four additional centres of paediatric cardiology in Germany, Israel, Italy and Spain. E.G.F.
Alloksys Life Sciences BV 19.02.2008
From October 2006 through February 2008 the Alloksys Life Sciences BV (Netherlands, www.alloksys.eu) was the sponsor of the clinical phase II trial 'APPIRED I' establishing the safety of intravenously administrated alkaline phosphatase in patients undergoing coronary artery bypass grafting (CABG) surgery with cardio-pulmonary bypass (CBP) (ClinicalTrials.gov-ID: NCT01010724). Efficacy, defined as reduction of pro-inflammatory responses compared to the placebo group patients, was shown. Subsequent studies are in preparation. E.G.F.
Arbeitsgemeinschaft Sklerotherapie 04.02.2008
Am 4. Feb. 2008 wurde der erste Patient in die Besenreisser-Studie der Arbeitsgemeinschaft Sklerotherapie in der Deutschen Gesellschaft für Phlebologie aufgenommen. Damit beginnt eine Reihe von Anwendungsbeobachtungen, die die Arbeitsgemeinschaft plant durchzuführen. E.G.F.
10.01.2008
Upon reviewing the web site of Aix Scientifics® the HON Foundation certified its full compliance with all HONcode principles. Aix Scientifics® is now accredited by the Health On the Net Foundation (HON), Geneva. The HON Foundation is a NonGovernmental Organization [NGO]. (click on the logo to verify) E.G.F.
NewCorTec S.r.l. Dec.2007
The study patient who received at 5th of July 2007 a BestBeat VAD (ventricle assist device of the NewCorTec S.r.l., Pomezia, Italy) implant at Niguarda Hospital, Milan, has been successfully heart transplanted. E.G.F.
Deutsche Gesellschaft für Transfusionsimmunologie 14.12.2007 : Der klinische Teil der deutsch-österreichischen Multizenter-Studie zur Sicherheit und Verträglichkeit der Dreifachthrombozytenspende wurde beendet. Von 426 Spendern wurden 2273 Apheresen erfasst. Im speziellen Teil der Studie wurden Daten zur Regulation der Thrombopoese nach intensivierter Thrombozytenspende untersucht. Beim Jahreskongres der DGTI 2007 konnte der Studienleiter PD Dr.med. Hans-Gert Heuft, Hannover, präliminär eine breite Akzeptanz des getesteten Verfahrens bei gesunden Spendern bei insgesamt guter Verträglichkeit berichten. Die Studie steht unter der Verantwortung der 'Sektion Präparative und therapeutische Hämapherese' der Deutschen Gesellschaft für Transfusionsmedizin und findet die Unterstützung der einschlägigen Unternehmen (Baxter, Fresenius, Gambro und Haemonetics). E.G.F.
NonWoTecc GmbH 06.12.2007
Today the NonWoTecc Medical GmbH, Cologne did start with animal research. E.G.F.
CardiaMed B.V. 28.09.2007
Op 28 oktober 2007 heeft CardiaMed B.V. zijn CE ontvangen , voor de verkoop van de CardiaMed hartklep. Deze hartklep is ontwikkeld in Rusland , waarvan er al veel meer dan 10.000 stuks met succes zijn geimplanteerd. Voor de toelating van onze hartklep werd nog een groot clinische onderzoek uitgevoerd. E.G.F.
Medical Engineering Company `MedEng´ 28.09.2007
On October 28, 2007 the Medical Engineering Company `MedEng´, Penza, and thereupon the CardiaMed B.V., Veghel, received the CE mark for their prosthetic heart valve. The ring as well as the two leaflets of this device are made of monolithic isotropic pyrolitic carbon. With no pivots on the leaflets the two leaflets rotate around the central axis of the valve housing. Although more than 10.000 prostheses have already implanted, a clinical study has been performed well in compliance with the standard ISO 5840:2005. E.G.F.
Aix Scientifics ® 01.09.1996
Aix Scientifics® was founded.
Aix Scientifics® è stata fondata. E.G.F.
 ( E.G.F. = Dr. Eike G. Fischer )
URL: http://www.aix-scientifics.ru/it/news.html     ( QR | DM  code)[19.05.2012 14:28]
Copyright © 1997-2012   Aix Scientifics® CRO, Aquisgrana (Aachen), Germania (ultima modificazione : 15.06.2010)
Impronta